Skip to content
The Biotechnology Innovation Organization (BIO) recently told the U.S. Patent and Trademark Office (USPTO) that proposed changes to the pharmaceutical patent process are flawed—and […]
BIO says that proposed changes to pharma patents would harm innovation Read More »
Partisan divisions were on display at a joint hearing of the House Energy & Commerce Committee’s Health and Oversight & Investigations subcommittees, as Republicans
Administration officials return to Congress to discuss COVID-19 response Read More »
Eleven years after the first CRISPR patent was filed, we’re anticipating what could be the first approval of a gene therapy based on CRISPR:
‘How do you price a cure?’ and other questions about the CRISPR era Read More »
In his State of the Union speech last night, President Joe Biden hailed the end of the COVID-19 emergency while ignoring the contribution of
State of the Union: Biden’s remarks on drug price controls and biomedical innovation Read More »
The number of new pain drugs in the development pipeline has slowed to a trickle and investment in addiction drugs is low, challenges addressed
‘All hands on deck’ needed to address U.S. pain and addiction innovation Read More »
The Inflation Reduction Act’s drug price controls have been a hot topic during the BIO CEO and Investor Conference—and one that has hampered an
We’re already seeing the impact of drug price controls, say biotech CEOs Read More »
“I think we’re in a very exciting time in healthcare and biotech,” said Steven Ladd, Director of Business Development and Acquisitions at AbbVie. “It’s
China-U.S. biotech ventures are where collaboration meets competition Read More »
On Friday, the Biotechnology Innovation Organization (BIO) submitted biotech regulation comments on the Administration’s Request for Information (RFI) “Identifying Ambiguities, Gaps, Inefficiencies, and Uncertainties in
BIO submits comments on framework for biotech regulation Read More »
The narrative is that it’s a bad market for biotech, but CEOs and investors told a packed house at the 2023 BIO CEO and
Are SPACs dead? – and other questions about the biotech market outlook Read More »
On Day 1 of the BIO CEO and Investor Conference, a panel—Prioritizing CRO Spending Through a High-Inflation, Sparse-Funding Period—brought together experts to look at
5 things to know about clinical trials Read More »
